A Phase III, double-blind, placebo-controlled intervention trial, where Diamyd^® (GAD-alum) is administered directly into lymph nodes in adolescents and adults with recently diagnosed Type 1 Diabetes, carrying the genetic HLA DR3-DQ2 haplotype. The trial evaluates the effectiveness of preserving the insulin producing capacity. This trial is conducted in six countries: Sweden, Spain, Poland, Germany, the Czech Republic and the Netherlands .

• 330 participants
• 12 − 29 years
• 24 mth duration
• Type 1 Diabetes

An open-label investigator-initiated clinical trial where Diamyd^® (GAD-alum) is given directly into the lymph node in type 1 diabetes patients carrying the genetically defined haplotype HLA DR3-DQ2 and previously treated with intralymphatic injections of Diamyd^® in the DIAGNODE-1 or DIAGNODE-2 trial. The aim of the trial is to evaluate the safety of a booster (fourth/fifth) injection with Diamyd^® and the effect on the immune system and the endogenous insulin production.

• 6 participants
• N/A
• 12 mth duration
• Type 1 Diabetes

An open label investigator initiated intervention trial with oral treatment of Remygen^®. The aim of the trial is to evaluate the safety of the treatment and the effect on the ability to regenerate insulin-producing beta cells.

• 30 participants
• 18 − 50 years
• 9 mth duration
• Type 1 Diabetes